||Relevant Treatment Approaches
RB1 E268* RB1 I101fs RB1 T738_R775del RB1 V654fs
Her2-receptor negative breast cancer
predicted - resistant
Fulvestrant + Palbociclib
In a clinical case study, RB1 mutations including E268*, I101fs, T738_R775del, and V654fs were identified in the circulating tumor DNA of a patient with estrogen receptor positive, progesterone receptor positive, and Erbb2 (Her2)-negative, invasive ductal carcinoma at the time of disease progression after 8 months of Ibrance (palbociclib) and Faslodex (fulvestrant) combination treatment (PMID: 29236940).